NurExone Biologic Inc.
NRX.V
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -1.68M | -1.77M | -1.40M | -1.47M | -1.85M |
| Total Depreciation and Amortization | 59.00K | 56.00K | 53.00K | 47.00K | 42.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 502.00K | 442.00K | 361.00K | 329.00K | 313.00K |
| Change in Net Operating Assets | 166.00K | 32.00K | -193.00K | -195.00K | 424.00K |
| Cash from Operations | -956.00K | -1.24M | -1.17M | -1.28M | -1.07M |
| Capital Expenditure | 2.00K | -2.00K | -9.00K | -12.00K | -2.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 2.00K | -2.00K | -9.00K | -12.00K | -2.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -9.00K | -8.00K | -10.00K | -8.00K | -1.00K |
| Issuance of Common Stock | 431.00K | 633.00K | 2.28M | 1.07M | 1.59M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 33.00K | -- | -- | -- | -- |
| Cash from Financing | 455.00K | 625.00K | 2.27M | 1.06M | 1.59M |
| Foreign Exchange rate Adjustments | 11.00K | -15.00K | 66.00K | -11.00K | 119.00K |
| Miscellaneous Cash Flow Adjustments | -16.00K | -- | -- | -- | -- |
| Net Change in Cash | -504.00K | -628.00K | 1.16M | -245.00K | 640.00K |